ZYME vs. ORIC, LYEL, GHRS, WVE, SIGA, NUVB, CVAC, VERV, MLYS, and PRAX
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include ORIC Pharmaceuticals (ORIC), Lyell Immunopharma (LYEL), GH Research (GHRS), Wave Life Sciences (WVE), SIGA Technologies (SIGA), Nuvation Bio (NUVB), CureVac (CVAC), Verve Therapeutics (VERV), Mineralys Therapeutics (MLYS), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical preparations" industry.
ORIC Pharmaceuticals (NASDAQ:ORIC) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
ORIC Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.
ORIC Pharmaceuticals has a net margin of 0.00% compared to ORIC Pharmaceuticals' net margin of -156.12%. ORIC Pharmaceuticals' return on equity of -26.20% beat Zymeworks' return on equity.
Zymeworks received 239 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 68.60% of users gave Zymeworks an outperform vote while only 65.22% of users gave ORIC Pharmaceuticals an outperform vote.
In the previous week, Zymeworks had 2 more articles in the media than ORIC Pharmaceuticals. MarketBeat recorded 3 mentions for Zymeworks and 1 mentions for ORIC Pharmaceuticals. Zymeworks' average media sentiment score of 0.59 beat ORIC Pharmaceuticals' score of 0.25 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media.
ORIC Pharmaceuticals has higher earnings, but lower revenue than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than ORIC Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 5.3% of ORIC Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
ORIC Pharmaceuticals currently has a consensus price target of $19.80, suggesting a potential upside of 145.35%. Zymeworks has a consensus price target of $15.00, suggesting a potential upside of 81.60%. Given Zymeworks' stronger consensus rating and higher probable upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than Zymeworks.
Summary
ORIC Pharmaceuticals beats Zymeworks on 9 of the 17 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
